Menu Search
Equities

Futura Medical PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
GYX:MUN

Futura Medical PLC

Actions
  • Price (EUR)0.0175
  • Today's Change0.00 / 0.00%
  • Shares traded20.00k
  • 1 Year change-91.50%
  • Beta2.3083
Data delayed at least 15 minutes, as of Feb 06 2026 07:38 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Futura Medical plc is a consumer healthcare company that specializes in the development and global commercialization of sexual health products. The Company is a developer of sexual health products, including the lead product, Eroxon, and two products in development, including WSD4000 and Eroxon Intense. Eroxon is a clear gel used for the treatment of erectile dysfunction (ED) available over the counter and without prescription and addresses significant unmet needs in the ED market. Eroxon Intense provides a potential range extension of the Eroxon product and acts as an additional treatment option for men who have ED. WSD4000 is a topical treatment designed for sexual dysfunction in women. The Company has distribution partners in place in a number of major consumer markets, including Haleon in the United States, and Cooper Consumer Health in Europe.

  • Revenue in GBP (TTM)7.93m
  • Net income in GBP-6.29m
  • Incorporated2001
  • Employees12.00
  • Location
    Futura Medical PLC40 Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
  • Phone+44 148 368 5670
  • Fax+44 148 368 5671
  • Websitehttps://www.futuramedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.